These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33152704)

  • 21. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer.
    Ulaner GA; Silverstein M; Nangia C; Tetef M; Vandermolen L; Coleman C; Khan S; MacDonald H; Patel T; Techasith T; Mauguen A
    JAMA Netw Open; 2024 Jul; 7(7):e2423435. PubMed ID: 39058489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
    Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
    Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
    Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Vogsen M; Jensen JD; Christensen IY; Gerke O; Jylling AMB; Larsen LB; Braad PE; Søe KL; Bille C; Ewertz M; Hildebrandt MG
    Breast Cancer Res Treat; 2021 Jan; 185(1):145-153. PubMed ID: 32920740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of
    Mercolini F; Zucchetta P; Jehanno N; Corradini N; Van Rijn RR; Rogers T; Cameron A; Scarzello G; Coppadoro B; Minard-Colin V; Gallego S; Chisholm J; Merks JH; Bisogno G
    Eur J Cancer; 2021 Sep; 155():155-162. PubMed ID: 34385068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control study.
    Xiao BB; Chen QY; Sun XS; Li JB; Luo DH; Sun R; Lin DF; Zhang X; Fan W; Lv XF; Han LJ; Wen YF; Yuan L; Guo SS; Liu LT; Liu SL; Tang QN; Liang YJ; Li XY; Lin C; Guo L; Mai HQ; Tang LQ
    Eur Radiol; 2021 Jul; 31(7):5222-5233. PubMed ID: 33416977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
    Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
    J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
    Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
    Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
    Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?
    Crivellaro C; Guglielmo P; De Ponti E; Elisei F; Guerra L; Magni S; La Manna M; Di Martino G; Landoni C; Buda A
    Medicine (Baltimore); 2017 Sep; 96(38):e7943. PubMed ID: 28930828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
    Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
    J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity, Specificity and the Diagnostic Accuracy of PET/CT for Axillary Staging in Patients With Stage I-III Cancer: A Systematic Review of The Literature.
    Kasem J; Wazir U; Mokbel K
    In Vivo; 2021; 35(1):23-30. PubMed ID: 33402446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.